Division of Neurovirology and Departments of Neurology and Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Annu Rev Pathol. 2013 Jan 24;8:189-215. doi: 10.1146/annurev-pathol-020712-164018. Epub 2012 Oct 18.
Since it was first described in 1958, progressive multifocal leukoencephalopathy (PML), a demyelinating disease of the brain caused by the polyomavirus JC (JCV), has evolved tremendously. It was once considered a noninflammatory disease that affected exclusively oligodendrocytes and astrocytes in the white matter of immunosuppressed individuals and was almost always fatal. Today, we understand that PML can present during the course of an immune reconstitution inflammatory syndrome and that it affects a broader range of individuals, including patients with minimal immunosuppression and those who are treated with novel immunomodulatory medications. Furthermore, JCV-infected glial cells are frequently located at the gray matter-white matter junction or within the gray matter, causing demyelinating lesions within cortical areas. Finally, JCV variants can also infect neurons, leading to the recognition of two distinct clinical entities: JCV granule cell neuronopathy and JCV encephalopathy.
自 1958 年首次描述以来,进行性多灶性白质脑病(PML)作为一种由多瘤病毒 JC(JCV)引起的脑脱髓鞘疾病,已经发生了巨大的变化。它曾经被认为是一种非炎症性疾病,仅影响免疫抑制个体的白质中的少突胶质细胞和星形胶质细胞,几乎总是致命的。如今,我们知道 PML 可以在免疫重建炎症综合征过程中出现,并且它影响的人群范围更广,包括免疫抑制程度最低的患者和接受新型免疫调节药物治疗的患者。此外,JCV 感染的神经胶质细胞经常位于灰质-白质交界处或灰质内,导致皮质区域内的脱髓鞘病变。最后,JCV 变体也可以感染神经元,导致两种不同的临床实体的识别:JCV 颗粒细胞神经元病和 JCV 脑病。